Cargando…

Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury

The detrimental effects of hypoxic damage to central nervous system lead to energy depletion, free radical formation, lipid peroxidation (LPO), and increased calcium. We hypothesized that in vitro tacrolimus (FK-506) and cyclosporine A (CsA) could be protective against hypoxic damage in spinal cord....

Descripción completa

Detalles Bibliográficos
Autores principales: Yousuf, Seema, Atif, Fahim, Kesherwani, Varun, Agrawal, Sandeep Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236540/
https://www.ncbi.nlm.nih.gov/pubmed/22399088
http://dx.doi.org/10.1002/brb3.16
_version_ 1782218763324620800
author Yousuf, Seema
Atif, Fahim
Kesherwani, Varun
Agrawal, Sandeep Kumar
author_facet Yousuf, Seema
Atif, Fahim
Kesherwani, Varun
Agrawal, Sandeep Kumar
author_sort Yousuf, Seema
collection PubMed
description The detrimental effects of hypoxic damage to central nervous system lead to energy depletion, free radical formation, lipid peroxidation (LPO), and increased calcium. We hypothesized that in vitro tacrolimus (FK-506) and cyclosporine A (CsA) could be protective against hypoxic damage in spinal cord. Dorsal columns were isolated from the spinal cord of adult rats and injured by exposure to hypoxic condition for 1 h, and treated with FK-506 (0.1 μM) and CsA (0.1 μM). After injury, reperfusion was carried out for 2 h. Tissues were collected, processed for biochemical assays, and 2,3,5-triphenyltetrazolium chloride (TTC) staining. Spinal cord hypoxia caused a significant decrease (P < 0.001) in mitochondrial ATP (30.64%) and tissue reduced glutathione (GSH) (60.14%) content. Conversely, a significant increase (P < 0.001) in tissue LPO level (57.77%) and myeloperoxidase (MPO) activity (461.24%) was observed in hypoxic group. Mitochondrial swelling was also significantly increased in hypoxic group (90.0%). Treatment with either FK-506 or CsA showed that significant neuroprotective effects (P < 0.05–0.01) were measured in various parameters in hypoxic groups. FK-506 and CsA treatment showed increase in ATP by 11.19% and 16.14% while GSH content increased by 66.46% and 77.32%, respectively. Conversely, LPO content decreased by 18.97% and 24.06% and MPO level by 42.86% and 18.66% after FK-506 and CsA treatment. Calcium uptake was also decreased in mitochondria as exhibited by the increase in absorbance by 11.19% after FK-506 treatment. TTC staining also showed increased viability after FK-506 and CsA treatment. In conclusion, present study demonstrates the neuroprotective effect of FK-506 and CsA treatment against spinal cord hypoxia induced damage is mediated via their antioxidant actions.
format Online
Article
Text
id pubmed-3236540
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Inc
record_format MEDLINE/PubMed
spelling pubmed-32365402011-12-23 Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury Yousuf, Seema Atif, Fahim Kesherwani, Varun Agrawal, Sandeep Kumar Brain Behav Original Research The detrimental effects of hypoxic damage to central nervous system lead to energy depletion, free radical formation, lipid peroxidation (LPO), and increased calcium. We hypothesized that in vitro tacrolimus (FK-506) and cyclosporine A (CsA) could be protective against hypoxic damage in spinal cord. Dorsal columns were isolated from the spinal cord of adult rats and injured by exposure to hypoxic condition for 1 h, and treated with FK-506 (0.1 μM) and CsA (0.1 μM). After injury, reperfusion was carried out for 2 h. Tissues were collected, processed for biochemical assays, and 2,3,5-triphenyltetrazolium chloride (TTC) staining. Spinal cord hypoxia caused a significant decrease (P < 0.001) in mitochondrial ATP (30.64%) and tissue reduced glutathione (GSH) (60.14%) content. Conversely, a significant increase (P < 0.001) in tissue LPO level (57.77%) and myeloperoxidase (MPO) activity (461.24%) was observed in hypoxic group. Mitochondrial swelling was also significantly increased in hypoxic group (90.0%). Treatment with either FK-506 or CsA showed that significant neuroprotective effects (P < 0.05–0.01) were measured in various parameters in hypoxic groups. FK-506 and CsA treatment showed increase in ATP by 11.19% and 16.14% while GSH content increased by 66.46% and 77.32%, respectively. Conversely, LPO content decreased by 18.97% and 24.06% and MPO level by 42.86% and 18.66% after FK-506 and CsA treatment. Calcium uptake was also decreased in mitochondria as exhibited by the increase in absorbance by 11.19% after FK-506 treatment. TTC staining also showed increased viability after FK-506 and CsA treatment. In conclusion, present study demonstrates the neuroprotective effect of FK-506 and CsA treatment against spinal cord hypoxia induced damage is mediated via their antioxidant actions. Blackwell Publishing Inc 2011-11 /pmc/articles/PMC3236540/ /pubmed/22399088 http://dx.doi.org/10.1002/brb3.16 Text en © 2011 The Authors. Published by Wiley Periodicals, Inc.
spellingShingle Original Research
Yousuf, Seema
Atif, Fahim
Kesherwani, Varun
Agrawal, Sandeep Kumar
Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title_full Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title_fullStr Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title_full_unstemmed Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title_short Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
title_sort neuroprotective effects of tacrolimus (fk-506) and cyclosporin (csa) in oxidative injury
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236540/
https://www.ncbi.nlm.nih.gov/pubmed/22399088
http://dx.doi.org/10.1002/brb3.16
work_keys_str_mv AT yousufseema neuroprotectiveeffectsoftacrolimusfk506andcyclosporincsainoxidativeinjury
AT atiffahim neuroprotectiveeffectsoftacrolimusfk506andcyclosporincsainoxidativeinjury
AT kesherwanivarun neuroprotectiveeffectsoftacrolimusfk506andcyclosporincsainoxidativeinjury
AT agrawalsandeepkumar neuroprotectiveeffectsoftacrolimusfk506andcyclosporincsainoxidativeinjury